Wieczorek L, Brown BK, Delsarto Macedo C, Wesberry-Schmierer M, Ngauy V, Rosa Borges A, Michael NL, Marovich MA, Montefiori DC, Polonis VR. Virology. Mitigation of variation observed in a peripheral blood mononuclear cell (PBMC) based HIV-1 neutralization assay by donor cell pooling. 2013 Dec; 447(1-2): 240-8. doi: 10.1016/j.virol.2013.09.014. Epub 2013 Oct 5.
Fahrbach KM, Malykhina O, Stieh DJ, Hope TJ (2013) Differential Binding of IgG and IgA to Mucus of the Female Reproductive Tract: e76176. PLos ONE. doi:10.1371/journal.pone.0076176
Beck Z, Jagodzinski L, Eller M, Thelian D, Matyas G, Kunz A, and Alving CR. Platelets and Erythrocyte-Bound Platelets Bind Infectious HIV-1 in Plasma of Chronically Infected Patients. PLoS One. 8(11):e81002. (2013)
Barouch DH1, Stephenson KE, Borducchi EN, Smith K, Stanley K, McNally AG, Liu J, Abbink P, Maxfield LF, Seaman MS, Dugast AS, Alter G, Ferguson M, Li W, Earl PL, Moss B, Giorgi EE, Szinger JJ, Eller LA, Billings EA, Rao M, Tovanabutra S, Sanders-Buell E, Weijtens M, Pau MG, Schuitemaker H, Robb ML, Kim JH, Korber BT, Michael NL. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell. 2013 Oct 24; 155(3):531-9. doi: 10.1016/j.cell.2013.09.061. Epub 2013 Oct 24.
Kijak GH, Pham P, Sanders-Buell E, Harbolick EA, Eller LA, Robb ML, Michael NL, Kim JH, Tovanabutra S. Nautilus: a bioinformatics package for the analysis of HIV type 1-targeted deep sequencing data. AIDS Res Hum Retroviruses. 2013 Oct; 29(10): 1361-4. doi: 10.1089/AID.2013.0175. Epub 2013 Aug 2.
Heipertz RA Jr, Sanders-Buell E, Kijak G, Howell S, Lazzaro M, Jagodzinski LL, Eggleston J, Peel S, Malia J, Armstrong A, Michael NL, Kim JH, O'Connell RJ, Scott PT, Brett-Major DM, Tovanabutra S. Molecular epidemiology of early and acute HIV type 1 infections in the United States Navy and Marine Corps. AIDS Res Hum Retroviruses. 2005-2010. 2013 Oct; 29(10): 1310-20. doi: 10.1089/AID.2013.0087.
Vaidya SA, Streeck H, Beckwith N, Ghebremichael M, Pereyra F, Kwon DS, Addo MM, Rychert J, Routy JP, Jessen H, Kelleher AD, Hecht F, Sekaly RP, Carrington M, Walker BD, Allen TM, Rosenberg ES, Altfeld M. “Temporal effect of HLA-B*57 on viral control during primary HIV-1 infection.” Retrovirology. 2013 Nov 18;10:139. doi: 10.1186/1742-4690-10-139. PubMed PMID: 24245727; PubMed Central PMCID: PMC3874665
Nilsson C, Godoy-Ramirez K, Hejdeman, B, Br.ve A, Gudmundsdotter L, Halleng.r D, Currier JR, Wieczorek L, Hasselrot K, Earl P, Polonis VR, Marovich MA, Robb MR, Sandstr.m E, Wahren B, Biberfeld G. "Broad and potent cellular and humoral immune responses after a second late HIV-MVA vaccination in HIV-DNA primed and HIV-MVA boosted Swedish vaccines."AIDS Res Hum Retroviruses. 014 Mar;30(3):299-311. doi: 10.1089/AID.2013.0149. Epub 2013 Nov 15.
Teigler JE1, Phogat S, Franchini G, Hirsch VM, Michael NL, Barouch DH.2014 The canarypox virus vector ALVAC induces distinct cytokine responses compared to the vaccinia virus-based vectors MVA and NYVAC in rhesus monkeys. J Virol. Feb; 88(3): 1809-14. doi: 10.1128/JVI.02386-13. Epub 2013 Nov 20.
Gottardo R, Bailer RT, Korber BT, Gnanakaran S, Phillips J, Shen X, Tomaras GD, Turk E, Imholte G, Eckler L, Wenschuh H, Zerweck J, Greene K, Gao H, Berman PW, Francis D, Sinangil F, Lee C, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Robb ML, Michael NL, Kim JH, Zolla-Pazner S, Haynes BF, Mascola JR, Self S, Gilbert P, Montefiori DC. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One. 2013 Sep 26;8(9): e75665. doi: 10.1371/journal.pone.0075665. eCollection 2013.
McLinden RJ, LaBranche CC, Chenine A-L, Polonis VR, Eller MA, et al. Detection of HIV-1 Neutralizing Antibodies in a Human CD4+/CXCR4+/CCR5+ T-Lymphoblastoid Cell Assay System: PLoS ONE. (2013) e77756 doi:10.1371/journal.pone.0077756
Mwafongo A1, Nkanaunena K, Zheng Y, Hogg E, Samaneka W, Mulenga L, Siika A, Currier J, Lockman S, Hughes MD, Hosseinipour M; AIDS Clinical Trial Group (ACTG) A5208 Team. Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine. AIDS. 2014 May 15;28(8):1135-42. doi: 10.1097/QAD.0000000000000202.
Mwau M, Adungo F, Kadima S, Njagi E, Kirwaye C, et al. (2013) Evaluation of PIMA™® Point of Care Technology for CD4 T Cell Enumeration in Kenya. PLoS ONE. 8(6): e67612. doi: 10.1371/journal.pone.0067612
Chung AW, Ghebremichael M, Robinson H, Brown E, Choi I, Lane S, Dugast AS, Schoen MK, Rolland M, Suscovich TJ, Mahan AE, Liao L, Streeck H, Andrews C, Rerks-Ngarm S, Nitayaphan S, de Souza MS, Kaewkungwal J, Pitisuttithum P, Francis D, Michael NL, Kim JH, Bailey-Kellogg C, Ackerman ME, Alter G. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci Transl Med. 2014 Mar 19;6(228):228ra38. doi: 10.1126/scitranslmed.3007736.
Cimbro, R.. Gallant, T., Dolan, M., Guzzo, C., Zhang, P., Lin, Y., Miao, H., Van Ryk, D., Arthos, J., Gorshkova, I., Brown, P., Hurt, D., and Lusso, P. Microbiology Tyrosine sulfation in the second variable loop (V2) of HIV-1 gp120 stabilizes V2–V3 interaction and modulates neutralization sensitivity. Proc Natl Acad Sci, USA. Feb 25, 2014; 111(8): 3152–3157. PMC3939864 Published online Feb 3, 2014. doi: 10.1073/pnas.1314718111
Shuying, S., Gilbert, P., Tomaras, G., Kijak, G., Gerrari, G., Thomas, R., Pyo, C., Zolla-Pazner, S., Montefiori, D., Liao, H., Nabel, G., Pinter, A., Evans, D., Gottardo, R., Dai, J., Janes, H., Morris, D., Fong, Y., Edlefsen, P., Li, F., Frahm, N., Alpert, M., Pretice, H., Rerks-Ngram, S., Pitisuttithum, P., Kaewkungwal, J., Nitayaphan, S., Robb, M., O’Connel, R., Haynes, B., Michael, N., Kim, J., McElrath, M., Geragthy, D. FCGR2C Polymorphisms Associate with HIV-1 vaccine protection in RV144 trial. Sep 2, 2014. Clin Invest. 2014;124(9): 3879-3890. doi:10.1172/JCI75539.
Robb, M., Michael, N. L. Phambili: Moving forward without the blindfold May 1, 2014 Vol. 14, Issue 5, 361-362 Lancet ID. DOI: 10.1016/S1473-3099(14)70029-5.
Dugast AS, Chan Y, Hoffner M, Licht A, Nkolola J, Li H, Streeck H, Suscovich TJ, Ghebremichael M Ackerman ME, Barouch DH, Alter G. “Lack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodies” PLoS One.2014 May 12;9(5):e97229. doi: 10.1371/journal.pone.0097229. eCollection 2014.
Jagodzinski LL, Liu Y, Hack HR, Kibirige C, Peel SA, et al. Discrepant Amplification Results during the Development of an Assay Leads to Reclassification of Two AIDS Reagent Repository HIV-2 Isolates as HIV-1: (2014) PLoS ONE. e96554. doi:10.1371/journal.pone.0096554.
Vandergeeten, C., Fromentin, R., Merlini, E., Bramah-Lawani, M., DaFonseca, S., Bakeman, W., McNulty, A., Ramgopal, M., Michael, N., Kim, J., Ananworanich, J., and Chomont, N. Cross-clade Ultrasensitive PCR-based Assays to Measure HIV Persistence in Large Cohort Studies. J. Virol. JVI.00609-14; 13 August 2014, doi:10.1128/JVI.00609-14.
Stieh, D., King, D., Klein, K., Liu, Shen, X., Hwang, K., Ferrari, G., Montefiori, D., Haynes, B., Pitisuttithum, P., Kaewkungwal, J., Nitayaphan, S., Rerks-Ngarm, S., Michael, N., Robb, M., Kim, J., Denny, T., Tomaras, G., Shattock, R. Aggregate complexes of HIV-1 induced by multimeric antibodies. VIRO (2014). doi:10.1186/s12977-014-0078-8 Published: 2 October 2014.
Excler JL, Robb ML, Kim JH. HIV-1 vaccines: Challenges and new perspectives. Hum Vaccin Immunother. 25. 2014 Jun 1;10(6):1734-1746. Epub 2014 Mar 17.
Pissani F, Streeck H. “Emerging concepts on T follicular helper cell dynamics in HIV infection.” Trends Immunol. 2014 Jun; 35(6):278-86. doi: 10.1016/j.it.2014.02.010. Epub 2014 Apr 2. Review. PubMed PMID: 24703588.
Naluyima P1, Eller MA, Laeyendecker O, Quinn TC, Serwadda D, Sewankambo NK, Gray RH, Michael NL, Wabwire-Mangen F, Robb ML, Sandberg JK. AIDS. Impaired natural killer cell responses are associated with loss of the highly activated NKG2A(+)CD57(+)CD56(dim) subset in HIV-1 subtype D infection in Uganda. 2014 Jun 1;28(9):1273-8. doi: 10.1097/QAD.0000000000000286.
Steers NJ, Currier JR, Jobe O, Tovanabutra S, Ratto-Kim S, Marovich MA, Kim JH, Michael NL, Alving CR, Rao M. Designing the epitope flanking regions for optimal generation of CTL epitopes. Vaccine. 2014 Jun 12;32(28):3509-16. doi: 10.1016/j.vaccine.2014.04.039. Epub 2014 May 2.
Zolla-Pazner, S., deCamp, A., Gilbert, P., Williams, C., Yates, N., Williams, W., Howington, R., Fong, Y., Morris, D., Soderberg, K., Irene, C., Reichman, C., Pinter, A., Tomaras, G. Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection Feb 04 2014 DOI: 10.1371/journal.pone.0087572
Fouda, G. G., et al. "Infant HIV Type 1 gp120 Vaccination Elicits Robust and Durable Anti-V1V2 Immunoglobulin G Responses and Only Rare Envelope-Specific Immunoglobulin A Responses." J Infect Dis. (2014). doi: 10.1093/infdis/jiu444
Whitney, J., Hill, A., Sanisetty, S., Penaloza-MacMaster, P. (2014) Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys Nature. doi:10.1038/nature13594 20 July 2014 doi:10.1038/nature13594
Asmelash A1, Zheng Y, Kaloustian KW, Shaffer D, Sawe F, Ogwu A, Salata R, Currier J, Hughes MD, Lockman S. Predictors of suboptimal CD4 response among women achieving virologic suppression in a randomized antiretroviral treatment trial, Africa. BMC Infect Dis. 2014 Jun 17;14:331. doi: 10.1186/1471-2334-14-331.
Khowsroy, K., Dhitavat, J., Sabmee, Y., Laowarakul, P., Wattanakitwichai, J., Auetian, J., Lothong, K., Boondao, R., Maythaarttaphong, S., Yaemwong, S., Excler, JL., Rerks-Ngarm, S., Pitisuttithum, P. Expectation of Volunteers Towards the Vaccine Efficacy of the Prime-Boost HIV Vaccine Phase III Trial During Unblinding. AIDS Res Hum Retroviruses. 2014 Jul 8.
Dugast AS, Stamatatos L, Tonelli A, Suscovich TJ, Licht AF, Mikell I, Ackerman ME, Streeck H, Klasse PJ, Moore JP, Alter G. “Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection”. 2014 Eur J. Immunol. Jul 10. doi: 10.1002/eji.201344305.
Shaffer D, Hughes MD, Sawe F, Bao Y, Moses A, Hogg E, Lockman S, Currier J. Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE). J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):155-63. Doi: 10.1097/QAI.00000000131.
Ehrenberg, P., Geretz, A., Baldwin, K., Apps, R., Polonis, V., Robb, M., Kim, J., Michael, N., Thomas, R. High-throughput multiplex HLA genotyping by next-generation sequencing using multi-locus individual tagging BMC Genomics (2014) 2014, 15:864 doi:10.1186/1471-2164-15-864
Torres, O., Jalah, R., Matyas, G. Characterization and optimization of heroin hapten-BSA conjugates: method development for the synthesis of reproducible hapten-based vaccines. Anal Bioanal Chem 2014 Sep 2;406(24):5927-37. Epub 2014 Aug 2.
Sosa-Batiz , A., Johnston, AP, Liu, H., Center, RJ., Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Kim, J., Michael, NL., Kelleher, AD., Stratov, I., Kent, SJ, Kramski, M. HIV-specific antibody-dependent phagocytosis matures during HIV infection. Immunol Cell Biol. 2014 Sep; 92(8):679-87. doi: 10.1038/icb.2014.42. Epub 2014 Jun 10.
Steers NJ, Currier JR, Jobe ,O., Tovanabutra ,S., Ratto-Kim, S., Marovich, MA., Kim, JH., Michael, NL, Alving, CR., Rao, M. Designing the epitope flanking regions for optimal generation of CTL epitopes. Vaccine. 2014 Jun 12;32(28):3509-16. doi: 10.1016/j.vaccine.2014.04.039. Epub 2014 May 2.
Kijak, G., Sanders-Buell, E., Harbolick, E., Phuc, Pham, Chenine, A., Eller, Rono, K., Robb, M., Michael, N., Jerome H. Kim, J., Tovanabutra, S. Targeted deep sequencing of HIV-1 using the IonTorrentPGM platform Journal of Virological Methods. Vol. 205, 1 September 2014.
Edlefsen PT, Rolland M, Hertz T, Tovanabutra S, Gartland AJ, deCamp AC, Magaret CA, Ahmed H, Gottardo R, Juraska M, McCoy C, Larsen BB, Sanders-Buell E, Carrico C, Menis S, Bose M, Arroyo MA, O'Connell RJ, deSouza MS, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Rerks-Ngarm S, Robb ML, McLellan JS, Georgiev IS, Kirys T, Kwong PD, Carlson JM, Michael NL, Schief WR, Mullins JI, Kim JH, Gilbert PB Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial. 2014 Oct;30 Suppl 1:A25-6. doi: 10.1089/aid.2014.5036.abstract.
Darpun, D Sachdev, Hasan, A., Huang, Y., Gilbert, P., Rerks-Ngarm, S., Kaewkungwal, J., Nitayaphan, S., Michael, N., Pitisuttithum, P., Robb, M., Kim,J., Frahm, N., Morgan, C., Buchbinder, S. Sex differences in Immune Variables in the RV144 Trial AIDS Res. Hum. Retroviruses AIDS Res Hum Retroviruses 2014 Oct;30 Suppl 1:A191.
Hughes, L., Hamm, T., Khamadi, S., Maganga, L., Kibuuka, H., Kiweewa, F., Njoku, O., Keshinro, B., Maswai, J., Aoko, A., Omondi, M., Otsyula, N., Polyak, C., Robb, M., Michael, N., Ake, J. The Relationship between Stigma, Disclosure, and Adherence among Participants in the African Cohort Study (AFRICOS). AIDS Research and Human Retroviruses: July 2014.
Tassaneetrithep, B., Tivon, D., James Swetnam, J., Nicos Karasavvas, N., Michael, NL., Kim, J., Marovich, M., Cardozo, T., Cryptic Determinant of α4β7 Binding in the V2 Loop of HIV-1 gp120. PLOS ONE: Sept. 29, 2014 DOI: 10.1371/journal.pone.010844.
Peachman, K., Billings, E., Rolland, M., McLinden, R., Chenine, A., Tovanabutra, S., Kim, J., Michael, N., Alving, C., and Rao, M. V2 Peptide Binding to HIV-1 Variants and Interaction of HIV-1 with α4β7 Integrin Receptor. AIDS Research and Human Retroviruses 29 (11) A54; 2013
Prentice H, Ehrenberg PK, Baldwin KM, Geretz A, Andrews C, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, O'Connell RJ, Robb ML, Kim JH, Michael NL, Thomas R. “HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial.” Immunogenetics. 2014 May;66(5):299-310. doi: 10.1007/s00251-014-0765-6. Epub 2014 Mar 29.
Streeck, H., Lu, R., Beckwith, N., Milazzo, M., Liu, M., Routy, J., Susan Little, S. Jessen, H., Kelleher, A., Hecht, F., Sekaly, R., Alter, G., Heckerman, D., Carrington, M., Rosenberg, E., Altfeld, M. Emergence of individual HIV-specific CD8 T cell responses during primary HIV-1 infection can determine long-term disease outcome. Journal of Virology: Aug. 2014; DOI: 10.1128/JVI.02016-14.
Robb ML, Kim JH. Shot in the HAART: vaccine therapy for HIV Lancet Infect Dis. 2014 Apr;14(4):259-60. doi: 10.1016/S1473-3099(13)70331-1. Epub 2014 Feb 11.
Alving CR, Matyas GR, Torres O, Jalah R, Beck Z. Adjuvants for vaccines to drugs of abuse and addiction. 2014 Sep 22; Vaccine:32(42):5382-9. doi: 10.1016/j.vaccine.2014.07.085.
Kim JH, Excler JL, Michael NL. Lessons from the RV144 Thai Phase III HIV-1 Vaccine Trial and the Search for Correlates of Protection. Annu Rev Med: 2014 Oct 17. Vol. 66 423-437. DOI: 10.1146/annurev-med-052912-123749
Torres OB, Jalah R, Rice KC, Li F, Antoline JF, Iyer MR, Jacobson AE, Boutaghou MN, Alving CR, Matyas GR. Characterization and optimization of heroin hapten-BSA conjugates: method development for the synthesis of reproducible hapten-based vaccines. Anal Bioanal Chem: 2014 Sep; 406(24):5927-37. doi: 10.1007/s00216-014-8035-x.
Gartland, A. J., et al. "Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial." J Virol. 2014 Aug; 88(15): 8242-8255.
Hu, H., et al. Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinantAd5-HIV vaccinated individuals. Proceedings of the National Academy of Sciences of the United States of America 111, 13439-13444 (2014).
Peachman, K.; Alving, C.; Rao, M. HIV-1 Envelope Variable Loop V2 and V3 Peptides Inhibit a4b7 Integrin Receptor Binding to MAdCAM-1. JAIDS: Nov., 2014 doi: 10.1097/01.qai.0000456197.87443.33
Yates, N. L., et al. (2014). "Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination." Sci Transl Med 6(228): 228ra239.
O'Connell RJ, Kim JH, Excler JL. The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development. Expert Rev Vaccines. Epub 2014 Aug 28. 2014 Dec;13(12):1489-500. doi:.1586/14760584.2014.951335.
Excler JL, Ake J, Robb ML, Kim JH, Plotkin SA. Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines 2014 Aug;21(8):1023-36. doi: 10.1128/CVI.00230-14. Epub 2014 Jun 11.
Jobe, O., Tovanabutra, S., Ehrenberg, P., Poltavee, K., Peachman, K., Chenine, A., McLinden, R., Thomas, R., Kim, J., Michael, N., Alving, C., Rao, M. Siglec-1 on Macrophages is a Major Infectivity Receptor for HIV-1: Differential Effects of GM-CSF and M-CSF on HIV-1 Entry and Replication. AIDS Research and Human Retroviruses 29 (11) A83; 2013.
Whitney, J., Hill, A., Sanisetty, S., Penaloza-MacMaster, P., Liu, J., Shetty, M., Parenteau, L., Cabral, C., Shields, J., Blackmore, S., Smith, J., Brinkman, A., Peter, L., Mathew, S.. Smith, K., Borducchi, E., Rosenbloom, D., Lewis, M., Hattersley, J., Li, B., Hesselgesser, J., Geleziunas, R., Robb, M., Kim, J., Michael, N. et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys (2014) doi:10.1038/nature13594 Published Online 20 July 2014.
Kim, J., Excler, J., Michael, N. (2014) Lessons from the RV144 Thai Phase III HIV-1 Vaccine Trial and the Search for Correlates of Protection. 2014 Oct 17. Epub 2014 Oct 17.
Kijak, G., Sanders-Buell, E., Chenine, A., Eller, M., Goonetilleke, N., Thomas, R., Leviyang, S., Harbolick, E., Bose, M., Pham, P., Oropeza, C., Poltavee, K., O'Sullivan, A., Merbah, M., Costanzo, M., Li, H., Fischer, W., Gao, F., Eller, L., O'Connell, R., Sinei, S., Maganga, L., Kibuuka, H., Nitayaphan, S., Rolland, M., Korber, B., McCutchan, F., Shaw, G., Michael, N., Robb, M., Tovanabutra, S., Kim, J. Cryptic Multiple HIV-1 Infection Revealed by Early, Frequent, and Deep Sampling during Acute Infection. 2014 Oct;30 Suppl 1:A58.
Prentice, H., Geraghty, D., Tomaras, G., Fong, Y., Nelson, W., Kijak, G., Zolla-Pazner, S., Nitayaphan, S., Rerks-Ngarm, S., Kaewkungwal, J., Pitisuttithum, P., Michael, N., Gilbert, P., Kim, J., Thomas, R. Immune Correlates Identified in the RV144 Vaccine Efficacy Trial Impact HIV-1 Acquisition Only in the Presence of Certain HLA Class II Genes. 2014 Oct;30 Suppl 1:A40